Explore the latest in heart failure with preserved ejection fraction from The JAMA Network, including its pathophysiology, treatment, and long-term outcomes.
This cohort study investigates whether myocardial fibrosis is similarly prevalent in both those with heart failure with preserved ejection fraction (HFpEF) and those at risk for HFpEF, similarly associating with disease severity and outcomes.
This study uses samples from the RELAX clinical trial to determine the effect of sildenafil treatment among individuals with heart failure with preserved ejection fraction.
This study evaluates the clinical predictors of troponin elevation and its association with in-hospital and long-term outcomes among patients with decompensated heart failure with preserved ejection fraction.
This study describes the diagnostic accuracy of technetium 99m pyrophosphate cardiac imaging for detecting transthyretin cardiac amyloidosis in patient with suspected disease.
This cohort study uses Swedish national registry data to compare mortality after coronary artery bypass grafting in patients with preoperative heart failure and reduced vs preserved ejection fraction.
This review examines evidence for the use of mineralocorticoid receptor antagonists in the treatment of heart failure and resistant hypertension.
This Viewpoint discusses management of heart failure with preserved ejection fraction (HFpEF) and lessons learned from the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial.
An anaylis of Swedish registy databases found that β-blockers reduced all-cause mortality but did reduce combined all-cause mortality or heart failure hospitalization among patients with preserved ejection fraction.